Table 1 Subsequent therapy.
ERd (n = 321) | Rd (n = 325) | |
|---|---|---|
Any subsequent therapy | 192 (60) | 213 (66) |
Most common subsequent therapya | ||
Dexamethasone | 170 (53) | 178 (55) |
Bortezomib | 122 (38) | 137 (42) |
Cyclophosphamide | 96 (30) | 99 (30) |
Pomalidomide | 82 (26) | 94 (29) |
Lenalidomide | 57 (18) | 71 (22) |
Carfilzomib | 47 (15) | 45 (14) |
Melphalan | 32 (10) | 35 (11) |
Bendamustine | 30 (9) | 27 (8) |
Thalidomide | 30 (9) | 42 (13) |
Daratumumab | 28 (9) | 38 (12) |
Doxorubicin | 19 (6) | 29 (9) |
Etoposide | 16 (5) | 17 (5) |
Prednisolone | 16 (5) | 14 (4) |
Prednisone | 15 (5) | 25 (8) |
Cisplatin | 15 (5) | 15 (5) |
